BioXcel MM
BioXcel Therapeutics
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name BioXcel MM as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 06:05 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07116694 · Assessment of Acute Psychomotor Agitation Measures Associated With Schizophrenia and Bipolar DisorderBioXcel Therapeutics Inc · completed · Bipolar I Disorder, Bipolar II Disorder, Schizophrenia · study chair
- Ph4NCT06041646 · Tachyphylaxis, Tolerance, & Withdrawal Post Treatment With Igalmi for Agitation in Schizophrenia or Bipolar DisorderBioXcel Therapeutics Inc · completed · Bipolar Disorder, Schizophrenia, Agitation,Psychomotor · study chair
- Ph3NCT05658510 · Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia and Bipolar Disorder (SERENITY III)BioXcel Therapeutics Inc · completed · Agitation,Psychomotor, Bipolar I Disorder, Bipolar II Disorder · study chair
- Ph2NCT05313386 · Study of BXCL501 In Agitation Associated With Delirium in ICU PatientsBioXcel Therapeutics Inc · withdrawn · Agitation, Delirium · study chair
- Ph2NCT05276830 · An Efficacy, and Safety Study Of BXCL501 For The Treatment Of Agitation Associated With DementiaBioXcel Therapeutics Inc · terminated · Agitation, Dementia · study chair
- Ph3NCT05271552 · Dexmedetomidine in the Treatment of Agitation Associated With Dementia (TRANQUILITY II)BioXcel Therapeutics Inc · completed · Agitation, Dementia · study chair
- Ph1NCT05025605 · Determining Efficacy and Safety of BXCL501 in Agitation Associated With Pediatric Schizophrenia and Bipolar DisorderBioXcel Therapeutics Inc · recruiting · Schizophrenia, Schizo-Affective Disorder, Schizophreniform; Schizophrenic · study chair
- Ph1/Ph2NCT04470050 · Dexmedetomidine in the Treatment of Symptoms Of Acute Opioid WithdrawalBioXcel Therapeutics Inc · completed · Opioid Withdrawal · study director
- Ph3NCT04276883 · Dexmedetomidine in the Treatment of Agitation Associated With Bipolar DisorderBioXcel Therapeutics Inc · completed · Agitation Associated With Bipolar Disorder, Agitation,Psychomotor, Bipolar Disorder · study chair
- Ph3NCT04268303 · Dexmedetomidine in the Treatment of Agitation Associated With SchizophreniaBioXcel Therapeutics Inc · completed · Agitation, Schizophrenia, Schizo Affective Disorder · study chair
- Ph1/Ph2NCT04251910 · Sub-Lingual Dexmedetomidine in Agitation Associated With DementiaBioXcel Therapeutics Inc · completed · Agitation,Psychomotor, Dementia · study chair
- Early Ph1NCT04123574 · A Pilot Study of BXCL701 in Patients With Pancreatic CancerBioXcel Therapeutics Inc · withdrawn · Cancer of Pancreas, Cancer of the Pancreas, Neoplasms, Pancreatic · study chair
- Ph1NCT04010305 · Sub-Lingual Dexmedetomidine in Agitation Associated With SchizophreniaBioXcel Therapeutics Inc · completed · Agitation, Schizophrenia · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-12 06:05 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 06:05 UTC. The ranking covers the 200 most relevant of 1 PubMed records, and a shared surname and initials can bring in a namesake. All 1 on PubMed
- Major depressive disorder and generalized anxiety disorder and response to treatment in hepatitis C patients in Egypt.Int J Psychiatry Med · 20152 citationsRCR 0.1